SG11202007805SA - Jak1 pathway inhibitors for the treatment of cytokine-related disorders - Google Patents

Jak1 pathway inhibitors for the treatment of cytokine-related disorders

Info

Publication number: SG11202007805SA
Authority: SG; Singapore
Prior art keywords: cytokine; treatment; related disorders; pathway inhibitors; jak1 pathway
Prior art date: 2018-02-16

Application number

SG11202007805SA

Inventor

Montgomery Michael O'neill

Ahmad Naim

Susan Snodgrass

Original Assignee

Incyte Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-02-16

Filing date

2019-02-14

Publication date

2020-09-29

2019-02-14 Application filed by Incyte Corp filed Critical Incyte Corp

2020-09-29 Publication of SG11202007805SA publication Critical patent/SG11202007805SA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Mycology (AREA)
Microbiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

SG11202007805SA 2018-02-16 2019-02-14 Jak1 pathway inhibitors for the treatment of cytokine-related disorders SG11202007805SA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201862710446P	2018-02-16	2018-02-16
US201862631825P	2018-02-18	2018-02-18
PCT/US2019/018066 WO2019161098A1 (en)	2018-02-16	2019-02-14	Jak1 pathway inhibitors for the treatment of cytokine-related disorders

Publications (1)

Publication Number	Publication Date
SG11202007805SA true SG11202007805SA (en)	2020-09-29

Family

ID=65529906

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202007805SA SG11202007805SA (en)	2018-02-16	2019-02-14	Jak1 pathway inhibitors for the treatment of cytokine-related disorders

Country Status (20)

Country	Link
US (3)	US11103510B2 (en)
EP (1)	EP3752146A1 (en)
JP (2)	JP2021513981A (en)
KR (1)	KR20200128043A (en)
CN (3)	CN118557580A (en)
AU (2)	AU2019221667B2 (en)
BR (3)	BR122023022247A2 (en)
CA (1)	CA3091339A1 (en)
CL (1)	CL2020002102A1 (en)
CO (1)	CO2020011388A2 (en)
EC (1)	ECSP20057643A (en)
IL (2)	IL311485A (en)
MA (1)	MA51829A (en)
MX (2)	MX2020008521A (en)
PE (1)	PE20212186A1 (en)
PH (1)	PH12020551251A1 (en)
SG (1)	SG11202007805SA (en)
TW (2)	TW202342026A (en)
UA (1)	UA127519C2 (en)
WO (1)	WO2019161098A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA117572C2 (en) *	2012-11-01	2018-08-27	Інсайт Холдинґс Корпорейшн	Tricyclic fused thiophene derivatives as jak inhibitors
SG11202007805SA (en)	2018-02-16	2020-09-29	Incyte Corp	Jak1 pathway inhibitors for the treatment of cytokine-related disorders
JP7565798B2 (en)	2018-03-30	2024-10-11	インサイト・コーポレイション	Biomarkers for Inflammatory Skin Disease
MA52208A (en)	2018-04-13	2021-02-17	Incyte Corp	BIOMARKERS FOR GRAFT-HOST DISEASE AGAINST HOST
MA54077A (en)	2018-10-31	2021-09-15	Incyte Corp	POLYTHERAPY FOR THE TREATMENT OF BLOOD DISEASES
EP3934651A1 (en)	2019-03-05	2022-01-12	Incyte Corporation	Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
WO2021026451A1 (en) *	2019-08-08	2021-02-11	Rigel Pharmaceuticals, Inc.	Compounds and method for treating cytokine release syndrome
US11992490B2 (en)	2019-10-16	2024-05-28	Incyte Corporation	Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
AU2021396231A1 (en) *	2020-12-08	2023-06-22	Incyte Corporation	Jak1 pathway inhibitors for the treatment of vitiligo
EP4333840A1 (en) *	2021-05-03	2024-03-13	Incyte Corporation	Jak1 pathway inhibitors for the treatment of prurigo nodularis
WO2024032527A1 (en) *	2022-08-08	2024-02-15	石药集团中奇制药技术（石家庄）有限公司	Use of compound containing tricyclic heteroaryl

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5521184A (en)	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
ATE459616T1 (en)	1998-08-11	2010-03-15	Novartis Ag	ISOCHINOLINE DERIVATIVES WITH ANGIOGENESIS-INHIBITING EFFECT
US6133031A (en)	1999-08-19	2000-10-17	Isis Pharmaceuticals Inc.	Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en)	1999-03-06	1999-04-28	Zeneca Ltd	Chemical compounds
GB0004890D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
ATE273695T1 (en)	2000-06-28	2004-09-15	Smithkline Beecham Plc	WET GRINDING
MXPA04002243A (en)	2001-09-19	2004-06-29	Aventis Pharma Sa	Chemical compounds.
KR20090087139A (en)	2001-10-30	2009-08-14	노파르티스 아게	Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
AR037647A1 (en)	2002-05-29	2004-12-01	Novartis Ag	USED DIARILUREA DERIVATIVES FOR THE TREATMENT OF DEPENDENT DISEASES OF THE PROTEIN KINase
GB0215676D0 (en)	2002-07-05	2002-08-14	Novartis Ag	Organic compounds
AR042052A1 (en)	2002-11-15	2005-06-08	Vertex Pharma	USEFUL DIAMINOTRIAZOLS AS INHIBITORS OF PROTEINQUINASES
UA80767C2 (en)	2002-12-20	2007-10-25	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en)	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
PE20050952A1 (en)	2003-09-24	2005-12-19	Novartis Ag	DERIVATIVES OF ISOQUINOLINE AS INHIBITORS OF B-RAF
US20060106020A1 (en)	2004-04-28	2006-05-18	Rodgers James D	Tetracyclic inhibitors of Janus kinases
MX2007006204A (en)	2004-11-24	2007-06-20	Novartis Ag	Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors.
AR054416A1 (en)	2004-12-22	2007-06-27	Incyte Corp	PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS.
WO2007038215A1 (en)	2005-09-22	2007-04-05	Incyte Corporation	Tetracyclic inhibitors of janus kinases
MX346183B (en)	2005-12-13	2017-03-10	Incyte Holdings Corp	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors.
JP5492565B2 (en)	2006-12-22	2014-05-14	インサイト・コーポレイション	Substituted heterocycles as JANUS kinase inhibitors
CL2008001709A1 (en)	2007-06-13	2008-11-03	Incyte Corp	Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
HUE029236T2 (en)	2007-06-13	2017-02-28	Incyte Holdings Corp	Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
KR101580482B1 (en)	2007-11-16	2015-12-28	인사이트 홀딩스 코포레이션	4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as Janus kinase inhibitors
PL2288610T3 (en)	2008-03-11	2017-12-29	Incyte Holdings Corporation	Azetidine and cyclobutane derivatives as jak inhibitors
CL2009001884A1 (en)	2008-10-02	2010-05-14	Incyte Holdings Corp	Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye.
JOP20190230A1 (en)	2009-01-15	2017-06-16	Incyte Corp	Processes for preparing jak inhibitors and related intermediate compounds
JP5775070B2 (en)	2009-05-22	2015-09-09	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	N- (hetero) aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo [2,3-d] pyrimidine and pyrrol-3-yl-pyrrolo [2,3-d] pyrimidine as Janus kinase inhibitors
PT2432472T (en)	2009-05-22	2019-12-09	Incyte Holdings Corp	3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
TW201113285A (en)	2009-09-01	2011-04-16	Incyte Corp	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PL2486041T3 (en)	2009-10-09	2014-01-31	Incyte Holdings Corp	Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
AU2011217961B2 (en)	2010-02-18	2016-05-05	Incyte Holdings Corporation	Cyclobutane and methylcyclobutane derivatives as Janus kinase inhibitors
ES2982015T3 (en) *	2010-03-10	2024-10-14	Incyte Holdings Corp	Piperidin-4-IL azetidine derivatives as JAK1 inhibitors
EP2558468B1 (en)	2010-04-14	2015-04-01	Array Biopharma, Inc.	5, 7-substituted-imidazo [1,2-c] pyrimidines as inhibitors of jak kinases
TWI499421B (en)	2010-05-21	2015-09-11	Incyte Corp	Topical formulation for a jak inhibitor
JOP20190250A1 (en)	2010-07-14	2017-06-16	Regeneron Pharma	Stabilized formulations containing anti-ngf antibodies
EP2640725B1 (en)	2010-11-19	2015-01-07	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CN103415515B (en)	2010-11-19	2015-08-26	因塞特公司	The pyrrolopyridine replaced as the cyclobutyl of JAK inhibitor and Pyrrolopyrimidine derivatives
WO2012076063A1 (en)	2010-12-10	2012-06-14	Rottapharm S.P.A.	Pyridine amide derivatives as ep4 receptor antagonists
CN103732226B (en)	2011-02-18	2016-01-06	诺瓦提斯药物公司	MTOR/JAK inhibitor combination treatment
EP2678686B1 (en)	2011-02-24	2017-10-11	Massachusetts Institute of Technology	ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER
PE20140832A1 (en)	2011-06-20	2014-07-14	Incyte Corp	DERIVATIVES OF AZETIDINYL PHENYL, PYRIDYL OR PYRAZINYL CARBOXAMIDE AS JAK INHIBITORS
WO2013023119A1 (en)	2011-08-10	2013-02-14	Novartis Pharma Ag	JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (en)	2011-08-18	2013-04-01	Incyte Corp	Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
ES2640911T3 (en)	2011-09-22	2017-11-07	Merck Sharp & Dohme Corp.	Cycloalkyl nitrilpyrazolcarboxamides as Janus kinase inhibitors
TW201406761A (en)	2012-05-18	2014-02-16	Incyte Corp	Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
UA117572C2 (en) *	2012-11-01	2018-08-27	Інсайт Холдинґс Корпорейшн	Tricyclic fused thiophene derivatives as jak inhibitors
AU2013344780B2 (en)	2012-11-15	2018-03-01	Incyte Holdings Corporation	Sustained-release dosage forms of ruxolitinib
KR102366356B1 (en)	2013-03-06	2022-02-23	인사이트 홀딩스 코포레이션	Processes and intermediates for making a jak inhibitor
EP2803668A1 (en)	2013-05-17	2014-11-19	Boehringer Ingelheim International Gmbh	Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US9371282B2 (en)	2013-05-17	2016-06-21	Centrexion Therapeutics Corporation	Somatostatin receptor subtype 4 (SSTR4) agonists
JO3603B1 (en)	2013-05-17	2020-07-05	Janssen Sciences Ireland Uc	Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
RS61482B1 (en)	2013-05-17	2021-03-31	Incyte Corp	Bipyrazole derivatives as jak inhibitors
EA201592126A1 (en)	2013-05-17	2016-05-31	Ф. Хоффманн-Ля Рош Аг	6-BRIDGED HETEROARYDYDYDROPYRIMIDIDES FOR THE TREATMENT AND PREVENTION OF HEPATITIS B VIRUS INFECTION
HUE049345T2 (en)	2013-08-07	2020-09-28	Incyte Corp	Sustained release dosage forms for a jak1 inhibitor
TW201529074A (en)	2013-08-20	2015-08-01	Incyte Corp	Survival benefit in patients with solid tumors with elevated C-reactive protein levels
AU2014339897A1 (en)	2013-10-24	2016-04-21	Abbvie Inc.	JAK1 selective inhibitor and uses thereof
SG10201807952PA (en)	2014-02-28	2018-10-30	Incyte Corp	Jak1 inhibitors for the treatment of myelodysplastic syndromes
CN106687462A (en)	2014-04-30	2017-05-17	因赛特公司	Processes of preparing a jak1 inhibitor and new forms thereto
US9498467B2 (en)	2014-05-30	2016-11-22	Incyte Corporation	Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
MA41185B1 (en)	2014-12-16	2019-12-31	Novartis Ag	Isoxazole hydroxamic acid compounds as lpxc inhibitors
EP4012415A3 (en)	2015-12-04	2022-12-07	Juno Therapeutics, Inc.	Methods and compositions related to toxicity associated with cell therapy
CN109476743A (en) *	2016-03-22	2019-03-15	西雅图儿童医院(以西雅图儿童研究所名义营业)	Prevention or the early intervention method for alleviating toxicity
CN110461315A (en) *	2016-07-15	2019-11-15	诺华股份有限公司	Cytokines release syndrome is treated and prevented using with the Chimeric antigen receptor of kinase inhibitor combination
WO2019040706A1 (en)	2017-08-24	2019-02-28	Aclaris Therapeutics, Inc.	Compositions and methods for treatment of vitiligo
AR113922A1 (en)	2017-12-08	2020-07-01	Incyte Corp	LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
IL276302B2 (en)	2018-01-30	2023-11-01	Incyte Corp	Processes for preparing [1-(3-fluoro-2-tripluoromethyl(isonicotinyl)piperidine-one]
SG11202007805SA (en)	2018-02-16	2020-09-29	Incyte Corp	Jak1 pathway inhibitors for the treatment of cytokine-related disorders
JP7565798B2 (en)	2018-03-30	2024-10-11	インサイト・コーポレイション	Biomarkers for Inflammatory Skin Disease
SI3773593T1 (en)	2018-03-30	2024-08-30	Incyte Corporation	Treatment of hidradenitis suppurativa using jak inhibitors
MA52208A (en)	2018-04-13	2021-02-17	Incyte Corp	BIOMARKERS FOR GRAFT-HOST DISEASE AGAINST HOST
JP2022526301A (en)	2019-03-19	2022-05-24	インサイト・コーポレイション	Biomarker of vitiligo vulgaris
PE20231102A1 (en)	2020-06-02	2023-07-19	Incyte Corp	PROCESSES FOR PREPARING A JAK1 INHIBITOR
TW202237125A (en)	2020-12-04	2022-10-01	美商英塞特公司	Jak inhibitor with a vitamin d analog for treatment of skin diseases
AU2021396231A1 (en)	2020-12-08	2023-06-22	Incyte Corporation	Jak1 pathway inhibitors for the treatment of vitiligo
EP4333840A1 (en)	2021-05-03	2024-03-13	Incyte Corporation	Jak1 pathway inhibitors for the treatment of prurigo nodularis

2019
- 2019-02-14 SG SG11202007805SA patent/SG11202007805SA/en unknown
- 2019-02-14 BR BR122023022247-4A patent/BR122023022247A2/en unknown
- 2019-02-14 IL IL311485A patent/IL311485A/en unknown
- 2019-02-14 MX MX2020008521A patent/MX2020008521A/en unknown
- 2019-02-14 WO PCT/US2019/018066 patent/WO2019161098A1/en active Application Filing
- 2019-02-14 US US16/276,157 patent/US11103510B2/en active Active
- 2019-02-14 JP JP2020543559A patent/JP2021513981A/en active Pending
- 2019-02-14 PE PE2020001231A patent/PE20212186A1/en unknown
- 2019-02-14 UA UAA202005910A patent/UA127519C2/en unknown
- 2019-02-14 MA MA051829A patent/MA51829A/en unknown
- 2019-02-14 BR BR122023022189-3A patent/BR122023022189A2/en unknown
- 2019-02-14 IL IL276725A patent/IL276725B2/en unknown
- 2019-02-14 CN CN202410646741.0A patent/CN118557580A/en active Pending
- 2019-02-14 KR KR1020207026669A patent/KR20200128043A/en active Application Filing
- 2019-02-14 CN CN202410646737.4A patent/CN118490690A/en active Pending
- 2019-02-14 EP EP19707655.7A patent/EP3752146A1/en active Pending
- 2019-02-14 BR BR112020016628-6A patent/BR112020016628A2/en unknown
- 2019-02-14 AU AU2019221667A patent/AU2019221667B2/en active Active
- 2019-02-14 CN CN201980024450.5A patent/CN111936135A/en active Pending
- 2019-02-14 CA CA3091339A patent/CA3091339A1/en active Pending
- 2019-02-15 TW TW112110278A patent/TW202342026A/en unknown
- 2019-02-15 TW TW108105190A patent/TWI799513B/en active
2020
- 2020-08-14 PH PH12020551251A patent/PH12020551251A1/en unknown
- 2020-08-14 MX MX2023003392A patent/MX2023003392A/en unknown
- 2020-08-14 CL CL2020002102A patent/CL2020002102A1/en unknown
- 2020-09-15 CO CONC2020/0011388A patent/CO2020011388A2/en unknown
- 2020-09-15 EC ECSENADI202057643A patent/ECSP20057643A/en unknown
2021
- 2021-07-19 US US17/379,336 patent/US11833152B2/en active Active
2023
- 2023-10-23 US US18/382,939 patent/US20240156818A1/en active Pending
- 2023-11-01 JP JP2023187800A patent/JP2024023213A/en active Pending
2024
- 2024-07-16 AU AU2024204891A patent/AU2024204891A1/en active Pending

Also Published As

Publication number	Publication date
TWI799513B (en)	2023-04-21
BR122023022189A2 (en)	2024-02-20
IL276725B1 (en)	2024-05-01
AU2019221667B2 (en)	2024-08-08
MX2020008521A (en)	2020-12-03
IL276725B2 (en)	2024-09-01
AU2019221667A1 (en)	2020-10-01
BR112020016628A2 (en)	2020-12-15
MA51829A (en)	2020-12-23
JP2024023213A (en)	2024-02-21
KR20200128043A (en)	2020-11-11
TW202342026A (en)	2023-11-01
ECSP20057643A (en)	2020-12-31
CN118490690A (en)	2024-08-16
AU2024204891A1 (en)	2024-08-01
US20240156818A1 (en)	2024-05-16
CO2020011388A2 (en)	2020-12-10
CN111936135A (en)	2020-11-13
TW202000203A (en)	2020-01-01
EP3752146A1 (en)	2020-12-23
IL276725A (en)	2020-09-30
IL311485A (en)	2024-05-01
BR122023022247A2 (en)	2024-02-20
PE20212186A1 (en)	2021-11-11
CN118557580A (en)	2024-08-30
US11103510B2 (en)	2021-08-31
MX2023003392A (en)	2023-06-16
JP2021513981A (en)	2021-06-03
CL2020002102A1 (en)	2021-01-29
WO2019161098A1 (en)	2019-08-22
US20190255053A1 (en)	2019-08-22
UA127519C2 (en)	2023-09-20
PH12020551251A1 (en)	2021-05-17
US20220040187A1 (en)	2022-02-10
US11833152B2 (en)	2023-12-05
CA3091339A1 (en)	2019-08-22

Publication	Publication Date	Title
IL276725A (en)	2020-09-30	Jak1 pathway inhibitors for the treatment of cytokine-related disorders
IL289650A (en)	2022-03-01	Azolopyrimidine for the treatment of cancer-related disorders
IL276032A (en)	2020-08-31	Compounds for the treatment of kinase-dependent disorders
IL271085A (en)	2020-01-30	Bacteria for the treatment of disorders
IL279260A (en)	2021-01-31	Kdm1a inhibitors for the treatment of disease
IL284034A (en)	2021-08-31	Jak1 pathway inhibitors for the treatment of gastrointestinal disease
IL285999A (en)	2021-10-31	Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
IL267818A (en)	2019-09-26	Methods for the treatment of neurological disorders
IL292690A (en)	2022-07-01	Mrgprx2 antagonists for the treatment of inflammatory disorders
IL276028A (en)	2020-08-31	Compounds for the treatment of kinase-dependent disorders
PL3380471T3 (en)	2021-12-20	Tetrahydro-8h-pyrido[1,2-a]pyrazine-8-ones as comt inhibitors for the treatment of neurodegenerative disorders
SG11202100092QA (en)	2021-02-25	USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS
IL276482A (en)	2020-09-30	Compounds for the treatment of pain
ZA202002993B (en)	2022-11-30	Compounds for the treatment of neuromuscular disorders
IL274067A (en)	2020-06-30	Kinase inhibitors for the treatment of central and peripheral nervous system disorders
IL288234A (en)	2022-01-01	Compounds for the treatment of neuromuscular disorders
IL284046A (en)	2021-08-31	Treatment of respiratory disorders with arachidonate15-lipoxygenase (alox15) inhibitors
IL276697A (en)	2020-09-30	3beta-(4-methoxybenzyloxy)pregn-5-en-20-one for use in the treatment of cannabinoids-related disorders
SG11202007642RA (en)	2020-09-29	Treatment of disorders with tasimelteon
PT3724173T (en)	2021-11-15	Compounds for the treatment of neuromuscular disorders